Thermo Fisher Scientific Inc. $TMO Stock Position Lifted by Wedmont Private Capital

Wedmont Private Capital lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 74.4% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 2,817 shares of the medical research company’s stock after buying an additional 1,202 shares during the quarter. Wedmont Private Capital’s holdings in Thermo Fisher Scientific were worth $1,837,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. BlackRock Inc. purchased a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $15,501,867,000. State Street Corp lifted its holdings in shares of Thermo Fisher Scientific by 1.4% in the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock valued at $9,633,991,000 after purchasing an additional 229,630 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Thermo Fisher Scientific during the second quarter valued at $1,974,561,000. Bank of America Corp DE acquired a new position in Thermo Fisher Scientific during the second quarter valued at $1,952,930,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Thermo Fisher Scientific by 0.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,428,731 shares of the medical research company’s stock worth $1,407,328,000 after acquiring an additional 13,728 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 420 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the sale, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 275 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $627.05, for a total value of $172,438.75. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $77,707,171.25. The trade was a 0.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 73,768 shares of company stock valued at $44,122,820. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Up 1.0%

NYSE:TMO opened at $658.23 on Friday. The company has a market capitalization of $243.38 billion, a P/E ratio of 35.41, a P/E/G ratio of 2.73 and a beta of 0.87. The stock’s 50 day moving average price is $627.39 and its 200 day moving average price is $541.36. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $694.33.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same period in the previous year, the company earned $4.28 earnings per share. The company’s revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on TMO shares. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $720.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, September 25th. Barclays raised their price target on shares of Thermo Fisher Scientific from $650.00 to $750.00 and gave the stock an “overweight” rating in a report on Wednesday. Jefferies Financial Group reiterated a “buy” rating and issued a $630.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Sanford C. Bernstein began coverage on shares of Thermo Fisher Scientific in a research note on Friday, June 26th. They set a “market perform” rating and a $520.00 target price for the company. Finally, Morgan Stanley boosted their price target on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $634.86.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.